Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tazarotene Clear all
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

NCT00648986
View directory record Official record
Conditions
Brittle Nails
Interventions
Tazorac
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 76 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

NCT01114841
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

NCT00440024
View directory record Official record
Conditions
Sun-Damaged Skin, Retinoid Intolerance
Interventions
Tazorac, Dove Mild Cleanser, Dove Facial Moisturizer
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

NCT03341910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%, Tazorac Vehicle Cream 0%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

NCT00834210
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone, Tazarotene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 4 Interventional

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

NCT00145106
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
Drug
Lead sponsor
KGL, Inc.
Other
Eligibility
12 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

NCT04720105
View directory record Official record
Conditions
Palmoplantar Psoriasis, Plaque Psoriasis
Interventions
Duobrii®
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

NCT03168321
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, IDP-123 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
42
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • La Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

NCT03292640
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03 (0.1% tazarotene) Lotion, DFD-03 (0% tazarotene) Lotion (Placebo)
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, Tazorac Cream, Vehicle Lotion, Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Encinitas, California • Fremont, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

NCT03168334
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, IDP-123 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Mobile, Alabama • Rogers, Arkansas • Carlsbad, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

NCT00489086
View directory record Official record
Conditions
Neoplastic Syndrome
Interventions
tazarotene
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

NCT02160665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

NCT02267746
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
14
States / cities
Encino, California • Fremont, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02462083
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
46
States / cities
Mobile, Alabama • Beverly Hills, California • Encinitas, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 23, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

NCT01017146
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Denver, Colorado • Miami Beach, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Results available

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756
View directory record Official record
Conditions
Solid Tumor, Hand-Foot Skin Reaction (HFSR)
Interventions
Topical Tazarotene, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 10:37 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 23, 2026, 10:37 AM EDT